It avoids synthetic hormones and harsh stimulants, making it gentler on the body and suitable for long-term use
The SURMOUNT-5 trial showed tirzepatide achieved 20.2% weight loss versus 13.7% for semaglutide
Originally developed to manage type 2 diabetes, GLP-1 receptor agonists have gained popularity for their appetite-suppressing and weight-loss effects, with the study finding that most prescriptions are now issued to women without diabetes
You typically start at a low dose of 0.8 mg and gradually increase your dosage over a period of 3090 days
For severe symptoms such as chest pain, severe shortness of breath or collapse, call 999
UPDATE: On August 21, 2023, CDE's website shows that Ei Lilly's Tirzepatide for weight control has been accepted for marketing authorization review, indicating that the competitive product is on the course to the Chinese obesity medication market